Kennedy moves to expand access to unproven peptides amid FDA concerns

Robert F. Kennedy Jr., the incoming U.S. health chief, is taking steps to broaden access to peptide-based treatments that have not completed standard regulatory approval processes. The move marks a significant departure from established FDA protocols governing experimental therapeutics and raises concerns among agency scientists about patient safety.

Peptides, chains of amino acids with potential therapeutic applications, have gained popularity in alternative medicine circles and among some wellness practitioners. However, most peptide treatments lack the rigorous clinical trial data and FDA approval required for mainstream medical use. Kennedy's initiative would potentially circumvent these safeguards, allowing wider distribution and use of these compounds.

FDA scientists have voiced opposition to the regulatory relaxation, arguing that existing approval frameworks exist to protect public health by ensuring drugs and biologics meet established standards for safety and efficacy. The internal resistance reflects long-standing institutional concerns about premature market access to untested medical interventions.

Kennedy, known for his skepticism toward conventional pharmaceutical regulatory frameworks, has championed alternative approaches to drug approval and access. His position as health policy leader gives him significant influence over FDA decision-making and regulatory direction.

Photo: Health and Human Services Secretary Robert F. Kennedy Jr. in his official portrait, February 2025. U.S. Department of Health and Human Services via Wikimedia Commons (public domain).